

Francesco Zaja

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9094131/francesco-zaja-publications-by-year.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

149 papers	7,697 citations	46 h-index	86 g-index
152 ext. papers	8,999 ext. citations	5.7 avg, IF	5 L-index

#	Paper	IF	Citations
149	Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience.. <i>Leukemia Research</i> , 2022 , 114, 106803	2.7	1
148	SF3B1-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation. <i>Haematologica</i> , 2021 , 106, 3125-3135	6.6	4
147	Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations. <i>Therapeutic Advances in Hematology</i> , 2021 , 12, 20406207211048361	5.7	1
146	Immune thrombocytopenia. <i>Expert Review of Hematology</i> , 2021 , 1-13	2.8	1
145	Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia. <i>Blood</i> , 2021 , 138, 571-583	2.2	4
144	Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2021 , 384, 1810-1823	59.2	28
143	Efficacy of recombinant erythropoietin in autoimmune hemolytic anemia: a multicenter international study. <i>Haematologica</i> , 2021 , 106, 622-625	6.6	16
142	Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study. <i>British Journal of Haematology</i> , 2021 , 193, 386-396	4.5	7
141	Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2021 , 27, 5566-5575	12.9	3
140	Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial. <i>Blood Advances</i> , 2021 , 5, 4504-4514	7.8	1
139	Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi.. <i>Frontiers in Oncology</i> , 2021 , 11, 789891	5.3	0
138	High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). <i>Haematologica</i> , 2020 , 105, 2671-2674	6.6	
137	Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation. <i>Hematological Oncology</i> , 2020 , 38, 257-265	1.3	4
136	CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression. <i>Blood</i> , 2020 , 135, 1244-1254	2.2	18
135	Biological and clinical implications of mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020 , 105, 448-456	6.6	35
134	ITP World Impact Survey (I-WISH) 2.0: Further Exploration of the Impact of ITP on Patients. <i>Blood</i> , 2020 , 136, 2-3	2.2	
133	A Phase II Study to Assess the Sustained Response Off Treatment in Patients with ITP Receiving Eltrombopag, Who Had a Previous Insufficient Response to Corticosteroids (TAPER): A Recruitment Update. <i>Blood</i> , 2020 , 136, 37-38	2.2	

132	Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection. <i>Leukemia</i> , 2020 , 34, 1462-1466	10.7	15
131	Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum. <i>Blood Advances</i> , 2020 , 4, 1013-1019	7.8	4
130	A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. <i>Haematologica</i> , 2020 , 105, 1613-1620	6.6	6
129	Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?. <i>Haematologica</i> , 2019 , 104, 1124-1135	6.6	27
128	A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines. <i>Haematologica</i> , 2019 , 104, e410-e414	6.6	2
127	Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma. <i>American Journal of Hematology</i> , 2019 , 94, 628-634	7.1	7
126	KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival. <i>Leukemia</i> , 2019 , 33, 2111-2115	10.7	10
125	MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients. <i>Haematologica</i> , 2019 , 104, e25-e28	6.6	17
124	Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT). <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2474-2481	4.7	16
123	Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. <i>Lancet Infectious Diseases</i> , 2019 , 19, 988-1000	25.5	82
122	Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. <i>Blood</i> , 2019 , 134, 1132-1143	2.2	46
121	Updated international consensus report on the investigation and management of primary immune thrombocytopenia. <i>Blood Advances</i> , 2019 , 3, 3780-3817	7.8	267
120	Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia. <i>Hematological Oncology</i> , 2019 , 37, 117-128	1.3	7
119	Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. <i>Blood</i> , 2019 , 133, 919-926	2.2	44
118	Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2904-2910	1.9	5
117	Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2113-2120	1.9	1
116	Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. <i>Journal of Experimental Medicine</i> , 2018 , 215, 681-697	16.6	41
115	Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials. <i>American Journal of Hematology</i> , 2018 , 93, 921-930	7.1	131

114	Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi. <i>Hematological Oncology</i> , 2018 , 36, 68-75	1.3	20
113	NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types. <i>British Journal of Haematology</i> , 2018 , 182, 597-602	4.5	15
112	Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers. <i>American Journal of Hematology</i> , 2018 , 93, 58-64	7.1	19
111	High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO. <i>British Journal of Haematology</i> , 2018 , 182, 807-815	4.5	8
110	Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study. <i>Blood</i> , 2018 , 132, 547-550	2.2	34
109	Eltrombopag As Second Line Therapy in Adult Patients with Primary Immune Thrombocytopenia (ITP) in Attempt to Achieve Long-Term Remission. Preliminary Analysis of a Phase II, Multicenter, Prospective Study By Gimema Group (the ESTIT Study). <i>Blood</i> , 2018 , 132, 1135-1135	2.2	2
108	Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1814-1828	1.9	15
107	Management of immune thrombocytopenia in elderly patients. <i>European Journal of Internal Medicine</i> , 2018 , 58, 70-76	3.9	5
106	A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1814-1822	4.7	10
105	The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study. <i>Leukemia and Lymphoma</i> , 2017 , 58, 226-229	1.9	4
104	Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2017 , 102, e203-e206	6.6	17
103	Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response. <i>European Journal of Haematology</i> , 2017 , 98, 371-377	3.8	42
102	Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial. <i>Lancet Haematology</i> , 2017 , 4, e137-e146	14.6	22
101	New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 821-836	5.4	3
100	Mutations in the 3' untranslated region of are associated with low CD20 expression levels chronic lymphocytic leukemia. <i>Haematologica</i> , 2017 , 102, e305-e309	6.6	11
99	Successful treatment and FDG-PET/CT monitoring of HHV-6 encephalitis in a non-neutropenic patient: case report and literature review. <i>Journal of NeuroVirology</i> , 2017 , 23, 908-912	3.9	5
98	Mutational status of is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia. <i>Haematologica</i> , 2017 , 102, e443-e446	6.6	8
97	Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , 2017 , 18, 1076-1088	21.7	72

96	Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia. <i>British Journal of Haematology</i> , 2017 , 176, 258-267	4.5	6
95	CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies?. <i>American Journal of Hematology</i> , 2017 , 92, E1-E2	7.1	22
94	Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1640-1647	1.9	8
93	Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1376-85	2.2	101
92	Lack of Prognostic Significance of the Conventional and Novel Prognostic Markers in Trisomy 12 Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2016 , 128, 4354-4354	2.2	
91	Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study. <i>American Journal of Hematology</i> , 2016 , 91, E293-5	7.1	25
90	Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. <i>Blood</i> , 2016 , 128, 2527-2532	2.2	115
89	Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin lymphoma: evidence from a multicenter, retrospective study. <i>Annals of Hematology</i> , 2016 , 95, 1107-14	3	19
88	Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2015 , 373, 1733-47	59.2	215
87	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. <i>Blood</i> , 2015 , 126, 1921-4	2.2	167
86	Brentuximab vedotin in combination with extended field radiotherapy as salvage treatment for primary refractory Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2015 , 90, E73	7.1	7
85	Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1671-6	1.9	17
84	Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2637-42	1.9	41
83	Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study. <i>Blood</i> , 2015 , 126, 2946-2946	2.2	1
82	Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice, the Lenamant Study. <i>Blood</i> , 2015 , 126, 3946-3946	2.2	3
81	The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells. <i>Oncotarget</i> , 2015 , 6, 19102-17	3.3	13
80	Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. <i>Leukemia Research</i> , 2014 , 38, 198-203	2.7	4
79	Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. <i>OncoTargets and Therapy</i> , 2014 , 7, 865-72	4.4	16

78	Two cases of concomitant diffuse large B-cell lymphoma and myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2014 , 89, 1011-3	7.1	4
77	MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years. <i>Neurology</i> , 2014 , 82, 1370-3	6.5	33
76	Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies. <i>Leukemia and Lymphoma</i> , 2014 , 55, 988-98	1.9	8
75	Bendamustine salvage therapy for T cell neoplasms. <i>Annals of Hematology</i> , 2013 , 92, 1249-54	3	25
74	Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. <i>European Journal of Haematology</i> , 2013 , 91, 546-51	3.8	37
73	Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. <i>MAbs</i> , 2013 , 5, 826-37	6.6	83
72	Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. <i>Journal of Hematology and Oncology</i> , 2013 , 6, 83	22.4	14
71	Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3351-9	2.2	48
70	HSV-1 cutaneous infection in a patient with Hodgkin $\text{\textcircled{L}}$ lymphoma treated with brentuximab vedotin. <i>Journal of Chemotherapy</i> , 2013 , 25, 381-2	2.3	2
69	Brentuximab vedotin in relapsed/refractory Hodgkin $\text{\textcircled{L}}$ lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. <i>Haematologica</i> , 2013 , 98, 1232-6	6.6	57
68	Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1442-9	2.2	137
67	Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice. <i>American Journal of Hematology</i> , 2013 , 88, 955-60	7.1	14
66	Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. <i>Blood</i> , 2013 , 121, 4902-5	2.2	94
65	Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. <i>Blood</i> , 2013 , 122, 3759-66	2.2	63
64	CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism. <i>Blood</i> , 2013 , 122, 3317-21	2.2	36
63	Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years. <i>Haematologica</i> , 2013 , 98, 875-80	6.6	76
62	Interim Analysis Of An Ongoing PHASE II Trial Assessing Safety and Efficacy Of Lenalidomide Maintenance In Patients With Chemosensitive Relapse Of Diffuse Large B-CELL Lymphoma (DLBCL). <i>Blood</i> , 2013 , 122, 3055-3055	2.2	
61	Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. <i>Cancer</i> , 2012 , 118, 434-43	6.4	77

60	Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab. <i>American Journal of Hematology</i> , 2012 , 87, 321-3	7.1	25
59	Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. <i>Haematologica</i> , 2012 , 97, 416-22	6.6	58
58	Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. <i>Blood</i> , 2012 , 119, 3691-7	2.2	93
57	Chlamydomphila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2988-94	2.2	125
56	Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL). <i>Annals of Hematology</i> , 2012 , 91, 1013-22	3	33
55	Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia. <i>American Journal of Hematology</i> , 2012 , 87, 886-9	7.1	40
54	Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: correlations with clinicobiologic parameters. <i>Blood</i> , 2012 , 119, 2310-3	2.2	57
53	Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy. <i>Clinical and Developmental Immunology</i> , 2012 , 2012, 638185		47
52	The Role of Rituximab in the Therapy of Mixed Cryoglobulinemia 2012 , 297-305		
51	Prognostic significance of delayed thrombocytopenia after allogeneic stem cell transplant. <i>American Journal of Hematology</i> , 2011 , 86, 790-2	7.1	8
50	ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. <i>New England Journal of Medicine</i> , 2011 , 365, 203-12	59.2	282
49	Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination. <i>Oncologist</i> , 2011 , 16, 336-41	5.7	27
48	Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network. <i>Leukemia and Lymphoma</i> , 2011 , 52, 2226-36	1.9	27
47	Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. <i>Blood</i> , 2010 , 115, 2755-62	2.2	199
46	Low-dose rituximab in adult patients with primary immune thrombocytopenia. <i>European Journal of Haematology</i> , 2010 , 85, 329-34	3.8	88
45	Salvage Treatment with Lenalidomide and Dexamethasone In Patients with Relapsed Refractory Mantle Cell Lymphoma: Clinical Results and Modifications of Angiogenic Biomarkers. <i>Blood</i> , 2010 , 116, 966-966	2.2	3
44	Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomycin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2009 , 50, 1824-9	1.9	4
43	High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. <i>Lancet, The</i> , 2009 , 374, 1512-20	40	478

42	Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. <i>Blood</i> , 2009 , 114, 4696-702	2.2	95
41	The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. <i>Blood</i> , 2009 , 114, 3167-72	2.2	169
40	Long Term Follow up Analysis Following Front Line Therapy with Dexamethasone or Dexamethasone Plus Rituximab in Adults with Primary Immune Thrombocytopenia.. <i>Blood</i> , 2009 , 114, 2415-2415	2.2	3
39	Low-Dose Rituximab in Idiopathic Autoimmune Hemolytic Anemia.. <i>Blood</i> , 2009 , 114, 4027-4027	2.2	1
38	Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results. <i>European Journal of Haematology</i> , 2008 , 81, 165-9	3.8	54
37	No evidences for B-cell clonality by spectratyping analysis in patients with idiopathic thrombocytopenic purpura undergoing rituximab therapy. <i>Haematologica</i> , 2008 , 93, 795-6	6.6	5
36	Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. <i>Haematologica</i> , 2008 , 93, 930-3	6.6	74
35	Trisomy 8 in chronic lymphocytic leukemia: a report of two cases. <i>Cancer Genetics and Cytogenetics</i> , 2007 , 175, 175-6		2
34	Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. <i>Blood</i> , 2007 , 110, 2316-23	2.2	260
33	A Prospective Randomized Study of Rituximab and Dexamethasone vs Dexamethasone Alone in ITP.. <i>Blood</i> , 2007 , 110, 567-567	2.2	2
32	The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. <i>Experimental Hematology</i> , 2006 , 34, 389-96	3.1	121
31	Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia. <i>Experimental Hematology</i> , 2006 , 34, 571-2	3.1	44
30	Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination. <i>Oncologist</i> , 2006 , 11, 285-91	5.7	51
29	Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. <i>Therapeutic Drug Monitoring</i> , 2005 , 27, 785-92	3.2	72
28	Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma. <i>Blood</i> , 2005 , 105, 3428-33	2.2	88
27	Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. <i>Cancer</i> , 2005 , 104, 2437-41	6.4	129
26	Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2654-61	2.2	123
25	Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. <i>European Journal of Cancer</i> , 2004 , 40, 1682-8	7.5	99

24	Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. <i>Blood</i> , 2004 , 103, 2474-9	2.2	460
23	Efficacy and safety of rituximab in type II mixed cryoglobulinemia. <i>Blood</i> , 2003 , 101, 3827-34	2.2	392
22	Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. <i>Leukemia and Lymphoma</i> , 2003 , 44, 1951-5	1.9	74
21	B-cell compartment as the selective target for the treatment of immune thrombocytopenias. <i>Haematologica</i> , 2003 , 88, 538-46	6.6	63
20	Endogenous endophthalmitis following disseminated fungemia due to <i>Fusarium solani</i> in a patient with acute myeloid leukemia. <i>European Journal of Haematology</i> , 2002 , 68, 314-7	3.8	27
19	Rituximab for the treatment of type II mixed cryoglobulinemia. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2252-4; author reply 2254-5		47
18	Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2029-33		219
17	Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. <i>Blood</i> , 2002 , 99, 856-62	2.2	147
16	Nocardiosis with favourable clinical outcome in progressive B-chronic lymphocytic leukaemia. <i>Leukemia and Lymphoma</i> , 2002 , 43, 1893-4	1.9	
15	B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. <i>Haematologica</i> , 2002 , 87, 189-95	6.6	83
14	Long-lasting complete remission of hepatitis C virus (HCV) infection and HCV-associated immunocytoma with alpha-interferon treatment. <i>British Journal of Haematology</i> , 2001 , 112, 370-2	4.5	38
13	Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. <i>Journal of Clinical Oncology</i> , 1999 , 17, 1254	2.2	229
12	The therapy of primary adult systemic CD30-positive anaplastic large cell lymphoma: results of 40 cases treated in a single center. <i>Leukemia and Lymphoma</i> , 1999 , 35, 159-69	1.9	18
11	Clinical features and outcome of multiple myeloma arising from the transformation of a monoclonal gammopathy of undetermined significance. <i>Leukemia and Lymphoma</i> , 1999 , 34, 591-6	1.9	6
10	BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine. <i>Leukemia and Lymphoma</i> , 1998 , 28, 567-72	1.9	28
9	Sequential intensive treatment with the F-MACHOP regimen (+/- radiotherapy) and autologous stem cell transplantation for primary systemic CD30 (Ki-1)--positive anaplastic large cell lymphoma in adults. <i>Leukemia and Lymphoma</i> , 1997 , 24, 369-77	1.9	10
8	Hepatitis C virus infection (and additional neoplasms) among marginal zone lymphomas. <i>British Journal of Haematology</i> , 1997 , 96, 427-8	4.5	14
7	Surgical staging in Hodgkin's disease: the role of laparoscopic splenectomy. <i>European Journal of Haematology</i> , 1996 , 57, 114-6	3.8	1

6	More on False Thrombocytopenias: EDTA-Dependent Pseudothrombocytopenia Associated with a Congenital Platelet Release Defect. <i>Vox Sanguinis</i> , 1996 , 71, 27-29	3.1	5
5	More on false thrombocytopenias: EDTA-dependent pseudothrombocytopenia associated with a congenital platelet release defect. <i>Vox Sanguinis</i> , 1996 , 71, 27-9	3.1	3
4	Magnetic resonance imaging and 67Ga scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: a prospective pilot study. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 1996 , 4, 213-24	2.8	22
3	Neutralizing anti-interferon-alpha antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (alpha 2a) and lymphoblastoid interferon-alpha. <i>British Journal of Haematology</i> , 1996 , 94, 300-5	4.5	15
2	Granulocyte colony-stimulating factor (G-CSF) allows the delivery of effective doses of CHOP and CVP regimens in non-Hodgkin lymphomas. <i>Leukemia and Lymphoma</i> , 1995 , 16, 465-70	1.9	6
1	Incidence and diagnosis of EDTA-dependent pseudothrombocytopenia in a consecutive outpatient population referred for isolated thrombocytopenia. <i>Vox Sanguinis</i> , 1995 , 68, 35-9	3.1	40